These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 24487783)

  • 21. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.
    Gao WL; Wie LL; Chao YG; Wie L; Song TL
    Clin Lab; 2012; 58(9-10):919-26. PubMed ID: 23163107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic utility of BRAF mutation in papillary thyroid cancer.
    Xing M
    Mol Cell Endocrinol; 2010 May; 321(1):86-93. PubMed ID: 19883729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The utility of BRAF testing in the management of papillary thyroid cancer.
    Melck AL; Yip L; Carty SE
    Oncologist; 2010; 15(12):1285-93. PubMed ID: 21147872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
    Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
    Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of the expression and potential molecular mechanism of interleukin-1 receptor antagonist (IL1RN) in papillary thyroid cancer via bioinformatics methods.
    Xie Z; Li X; He Y; Wu S; Wang S; Sun J; He Y; Lun Y; Xin S; Zhang J
    BMC Cancer; 2020 Nov; 20(1):1143. PubMed ID: 33238942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
    Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
    Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathologic diagnosis of papillary thyroid carcinoma: today and tomorrow.
    Baloch ZW; LiVolsi VA
    Expert Rev Mol Diagn; 2005 Jul; 5(4):573-84. PubMed ID: 16013975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical prognosis in BRAF-mutated PTC.
    Puxeddu E; Moretti S
    Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):736-47. PubMed ID: 17891237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma.
    Chen D; Qi W; Zhang P; Zhang Y; Liu Y; Guan H; Wang L
    Pathol Res Pract; 2018 Feb; 214(2):303-307. PubMed ID: 29254799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
    Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the expression levels of BRAF
    Tran TV; Dang KX; Pham QH; Nguyen UD; Trinh NTT; Hoang LV; Ho SA; Nguyen BV; Nguyen DT; Trinh DT; Tran DN; Orpana A; Stenman UH; Stenman J; Ho TH
    BMC Cancer; 2020 May; 20(1):368. PubMed ID: 32357861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF
    Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T
    Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Morphological parameters able to predict BRAF(V600E) -mutated malignancies on thyroid fine-needle aspiration cytology: Our institutional experience.
    Rossi ED; Bizzarro T; Martini M; Capodimonti S; Fadda G; Larocca LM; Schmitt F
    Cancer Cytopathol; 2014 Dec; 122(12):883-91. PubMed ID: 25156883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HER-2÷neu expression in different histological subtypes of papillary thyroid carcinoma.
    Ciobanu Apostol D; Căruntu ID; Lozneanu L; Andriescu EC; Giuşcă SE
    Rom J Morphol Embryol; 2017; 58(2):439-444. PubMed ID: 28730228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of VHL tumor suppressor mRNA and miR-92a in papillary thyroid carcinoma and their correlation with clinical and pathological parameters.
    Todorović L; Stanojević B; Mandušić V; Petrović N; Živaljević V; Paunović I; Diklić A; Saenko V; Yamashita S
    Med Oncol; 2018 Jan; 35(2):17. PubMed ID: 29340905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Upregulation of the ESR1 Gene and ESR Ratio (ESR1/ESR2) is Associated with a Worse Prognosis in Papillary Thyroid Carcinoma: The Impact of the Estrogen Receptor α/β Expression on Clinical Outcomes in Papillary Thyroid Carcinoma Patients.
    Yi JW; Kim SJ; Kim JK; Seong CY; Yu HW; Chai YJ; Choi JY; Lee KE
    Ann Surg Oncol; 2017 Nov; 24(12):3754-3762. PubMed ID: 28124274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
    Nicolussi A; D'Inzeo S; Mincione G; Buffone A; Di Marcantonio MC; Cotellese R; Cichella A; Capalbo C; Di Gioia C; Nardi F; Giannini G; Coppa A
    Int J Oncol; 2014 Feb; 44(2):548-56. PubMed ID: 24316730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene.
    Lin JD; Fu SS; Chen JY; Lee CH; Chau WK; Cheng CW; Wang YH; Lin YF; Fang WF; Tang KT
    Thyroid; 2016 May; 26(5):691-704. PubMed ID: 26914762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
    Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
    Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.